

Tazorac® (tazarotene) - First-time generic

- On September 15, 2022, Cosette launched an <u>AB-rated</u> generic version of Allergan's <u>Tazorac</u> (tazarotene) gel.
 - Cosette's generic Tazorac gel received 180-days of competitive generic therapy exclusivity.
- Tazorac is approved for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement, and the topical treatment of patients with facial acne vulgaris of mild to moderate severity.
- Tazarotene is also available generically as a <u>cream</u> and a <u>foam</u>, and a brand lotion (<u>Arazlo®</u>) and a brand combination lotion (<u>Duobrii® [halobetasol/tazarotene]</u>).
 - The cream is approved for similar indications as Tazorac gel.
 - The foam is approved for the topical treatment of acne vulgaris in patients 12 years of age or older.
 - Arazlo is approved for the topical treatment of acne vulgaris in patients 9 years of age and older.
 - Duobrii is approved for the topical treatment of plaque psoriasis in adults.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.